Eric Jurgens, MD
We post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
Conditions I Treat
- Multiple myeloma and other plasma-cell diseases
- Light chain (AL) amyloidosis
My Specialties
- Stem cell transplant
- Cellular therapy
- CAR T-cell therapy
Get to Know Me
I’m a medical oncologist and hematologist who cares for people with multiple myeloma and other plasma cell disorders such as AL amyloidosis.
I’m specially trained in stem cell transplantation and cellular therapy approaches to treating people with multiple myeloma. I partner with patients and their families at every step of their cancer treatment journey. We work together to develop a treatment plan that reflects each person’s needs and goals.
I see patients at Memorial Hospital, the main hospital at Memorial Sloan Kettering Cancer Center (MSK) and the David H. Koch Center for Cancer Care at MSK in New York City. I also see patients at MSK Nassau on Long Island.
My research focuses on clinical trials and translational studies that study the latest immunotherapies for multiple myeloma. This includes CAR T cell therapy and bispecific antibodies that use your body’s own immune system to fight cancer cells.
I have a special interest in improving the safety and efficacy of these therapies. I also focus on new treatment approaches for patients with multiple myeloma.
I'm a bone marrow transplant specialist, which is a doctor with special training in bone marrow transplants.
A cellular therapy specialist is a doctor with special training in using cell therapies to treat health conditions such as cancer. Therapies can include chimeric antigen receptor (CAR) T cell therapy.
- Assistant Attending Physician
Conditions I Treat
- Multiple myeloma and other plasma-cell diseases
- Light chain (AL) amyloidosis
My Specialties
- Stem cell transplant
- Cellular therapy
- CAR T-cell therapy
- Bispecific antibodies
- Clinical trials
Education
- Bachelor of Science, Cornell University
- MD, Weill Cornell Medical College
Residencies
- Internal Medicine, NewYork-Presbyterian/Weill Cornell
Fellowships
- Medical Oncology & Hematology, Memorial Sloan Kettering Cancer Center
Board Certifications
- Internal Medicine
- Medical Oncology
- Hematology
Awards and Honors
- Young Investigator Award, American Society of Clinical Oncology (2024-2025)
- Young Investigator Award, International Myeloma Society (2024-2025)
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
HMO, EPO PPO, POS, Transplant
In Network Coverage Type
PPO
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
HMO
This plan is in-network at our New York sites only.
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
Supplemental
In Network Coverage Type
PPO, POS, HMO
In Network Coverage Type
POS, HMO
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
HMO
This plan is in-network at our New York sites only.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
HMO
This plan is in-network at our New York sites only.
In Network Coverage Type
PPO
This is a dual payer plan, which means 2 health insurance companies share this plan. MSK providers are out-of-network with UnitedHealthcare.
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
HMO
This plan is in-network at our New York sites only.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
This plan is in-network at our New York sites only.
In Network Coverage Type
HMO, PPO
In Network Coverage Type
PPO EPO
In Network Coverage Type
HMO
Your plan may not cover visits to our New York sites. Please call the number on the back of your insurance card to see what your health plan covers.
In Network Coverage Type
PPO
Your plan may not cover visits to our New York sites. Please call the number on the back of your insurance card to see what your health plan covers.
In Network Coverage Type
EPO
Your plan may not cover visits to our New York sites. Please call the number on the back of your insurance card to see what your health plan covers.
In Network Coverage Type
EPO
Your plan may not cover visits to our New York sites. Please call the number on the back of your insurance card to see what your health plan covers.
In Network Coverage Type
PPO, HMO
Your plan may not cover visits to our New York sites. Please call the number on the back of your insurance card to see what your health plan covers.
In Network Coverage Type
State Government
This plan is in-network at our New York sites only.
In Network Coverage Type
PPO, POS, EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
HMO (City Employee Health Plans Gold and Gold Care Only)
In Network Coverage Type
Supplemental
In Network Coverage Type
PPO/OAP
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
TBD
In Network Coverage Type
PPO, EPO
In Network Coverage Type
PPO, POS, HMO
In Network Coverage Type
State Government
This plan is in-network at our New York sites only.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO, POS
In Network Coverage Type
PPO, POS, HMO
In Network Coverage Type
State Government
Learn more about the insurance plans that participate with MSK.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
Health plans can change at any time. Call the number on the back of your insurance card to see what your plan covers. Make sure it covers the MSK location where you’ll get care.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
Contact and Location
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
- Jurgens EM, Mitra S, Herrera K, Nemirovsky D, Bready B, Derkach A, Hosszu K, McAvoy D, Firestone RS, Rajeeve S, Lesokhin AM. Robust CD4+ CAR T cell expansion is associated with non-ICANS neurotoxicities after ciltacabtagene autoleucel in patients with multiple myeloma. Science Translational Medicine. 2026 Jul 29.
- Kostiou V, Chelliah V, van der Graaf PH, Kierzek AM, Farzana T, Mailankody S, Jurgens EM. Patient‐Specific Determinants of Response to BCMA‐and GPRC5D‐Targeted CAR T‐Cell Therapy in Multiple Myeloma: A QSP Analysis of Clinical Trial and Real‐World Data. Clinical Pharmacology & Therapeutics. 2026 Jun 27.
- Jurgens EM, Mailankody S. CAR T cells take on precancers. Nature Medicine. 2026 Jul.
- Jurgens E, Shekarkhand T, Rueda C, Nemirovsky D, Derkach A, Firestone RS, Miller K, Costa BA, Rajeeve S, Lesokhin AM, Korde N. Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma. Blood Cancer Journal. 2025 Nov 1.
- Jurgens EM, Firestone RS, Chaudhari J, Hosszu K, Devlin SM, Shah UA, Landa J, McAvoy DP, Lesokhin AM, Korde N, Hassoun H. Phase I trial of MCARH109, a G protein–Coupled receptor class C group 5 member D (GPRC5D)–Targeted chimeric antigen receptor T-cell therapy for Multiple myeloma: an updated analysis. Journal of Clinical Oncology. 2025 Feb 10.
Visit PubMed for a full listing of Dr. Jurgens’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.